Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC Update - January 2017

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

Buprenorphine transdermal patch (Butec®) has been accepted for restricted use in adults, for the treatment of chronic non-malignant pain of moderate intensity when an opioid is necessary for obtaining adequate analgesia. The restriction limits use to elderly patients (over 65 years).

Conjugated oestrogens and bazedoxifene acetate (Duavive®) has been rejected in the treatment of oestrogen deficiency symptoms in postmenopausal women with a uterus (with at least 12 months since the last menses) for whom treatment with progestin-containing therapy is not appropriate. The manufacturer failed to make a submission.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - January 2017' on Email Share 'SMC Update - January 2017' on Delicious Share 'SMC Update - January 2017' on Digg Share 'SMC Update - January 2017' on Facebook Share 'SMC Update - January 2017' on reddit Share 'SMC Update - January 2017' on StumbleUpon Share 'SMC Update - January 2017' on Twitter

atomic-wealth

No Comments to “SMC Update - January 2017”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by ClassicPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.

atomic-wealth
fond-illness
summer